Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Gritstone Oncology" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Gritstone Oncology for you to read. Along with our medical data and news we also list Gritstone Oncology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Gritstone Oncology Companies for you to search.
bluebird bio (NASDAQ:BLUE) and Gritstone Oncology announced Thursday (August 23) in a joint press release the two will research, develop and commercialize oncology cell therapy treatments. The post bluebird bio and Gritstone Oncology to Collaborate appeared first on Investing News Network.
US-based biotechnology companies Bluebird Bio and Gritstone Oncology have entered into strategic collaboration for the development of new cancer cell...Read More... The post Bluebird Bio and Gritstone Oncology partner on cancer cell therapies appeared first on Pharmaceutical Technology.
Gritstone Oncology Inc. (cancer immunotherapies) received $10mm through an investment in its Series C preferred shares from n...
Gritstone Oncology Inc. (cancer immunotherapies) raised $21mm through its Series C round, including a $10mm investment from n...
CAMBRIDGE, Mass. & EMERYVILLE, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify t...
Gritstone to be Issued Patent for its EDGE™ Deep Learning Model to Identify Neoantigens for Inclusion in Personalized Cancer Immunotherapies Read more...
An upsized initial public offering pulled in $100 million for Gritstone Oncology. -More-
Bristol-Myers Squibb Co. and Gritstone Oncology will together evaluate immunotherapy combinations for advanced solid tumors. ...
NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), and Opdivo plus Yervoy (ipilimumab), in patients with advanced solid tumors.
EMERYVILLE, Calif. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001, which comprises sequential delivery of neoantigens to patients within an adeno...
Personalized neoantigen therapeutics company Gritstone Oncology netted $93mm through its initial public offering of 6.67mm co...
Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Cambridge, Mass.-based bluebird bio and Gritstone Oncology inked a deal to combine gene and cell therapies to target cancer. This morning California-based Gritstone said it will leverage its artificial intelligence platform, dubbed EDGE, to analyze specific tumor types for the collaboration.
Bluebird bio and Gritstone Oncology have partnered to develop cell therapies for 10 tumor-specific targets for various tumor -More-
bluebird bio will use Gritstone Oncology’s artificial intelligence (AI) platform to research, develop and commercialize T-cell receptor (TCR) directed cell therapies for cancer, under a collaboration that could generate more than $30 million for Gritstone, the companies said today. Gritstone will use its EDGE™ (Epitope Discovery in cancer GEnomes) tumor-specific neoantigen (TSNA) identific...
Personalized neoantigen therapeutics company Gritstone Oncology has filed for its initial public offering.
Bristol-Myers Squibb Company has entered a clinical trial collaboration with Gritstone Oncology to examine the safety and tolerability of GRANITE-001...Read More... The post Bristol-Myers Squibb and Gritstone to start Phase l trial for tumours appeared first on Drug Development Technology.
Gritstone Oncology will leverage its proprietary EDGE artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets The post bluebird bio, Gritstone partner to develop cancer cell therapies appeared first on Pharma Business review.
Gritstone Oncology agreed to use its EDGE personalized neoantigen platform to provide ten tumor-specific targets (and T-cell ...
The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts. Gritstone Oncology (NASDAQ: GRTS) closed out the week by raising $100 million in an upsized IPO. On Thursday night, Emeryville, CA-based Gritstone priced its […]